Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Download Data

Tenaya Therapeutics Inc Net Working Capital to Total Assets Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -9.87%

Tenaya Therapeutics Inc Net Working Capital to Total Assets Ratio 3 year CAGR is -9.87% for the Trailing 12 Months (TTM) ending March 31, 2024. The net working capital to total assets ratio measures the proportion of a company's net working capital (current assets minus current liabilities) to its total assets. It is calculated by dividing the net working capital by the total assets. This ratio indicates the percentage of a company's total assets that are financed by its net working capital. A higher ratio suggests a greater reliance on working capital to fund the company's operations and indicates a potential liquidity cushion. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tenaya Therapeutics Inc Net Working Capital to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.61, a -16.63% change year over year.
Tenaya Therapeutics Inc Net Working Capital to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.73, a -10.05% change year over year.
Tenaya Therapeutics Inc Net Working Capital to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.81.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends